These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 29611754)

  • 1. Experience with eribulin in triple-negative metastatic breast cancer: case studies.
    Gallegos Sancho MI; Márquez-Vázquez R; Sánchez-Muñoz A
    Future Oncol; 2018 Mar; 14(7s):13-20. PubMed ID: 29611754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Lasting Exceptional Radiological Complete Response after Treatment with Eribulin in a Patient with Triple-Negative Breast Cancer with Liver Involvement.
    Dottorini L; Catena L; Sarno I; Di Menna G; Marte A; Bajetta E
    Oncology; 2018; 94 Suppl 1(Suppl 1):6-9. PubMed ID: 30036862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy.
    Pivot X; Marmé F; Koenigsberg R; Guo M; Berrak E; Wolfer A
    Ann Oncol; 2016 Aug; 27(8):1525-31. PubMed ID: 27177860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer.
    Kashiwagi S; Fukushima W; Asano Y; Goto W; Takada K; Noda S; Takashima T; Onoda N; Ohsawa M; Hirakawa K; Ohira M
    BMC Cancer; 2017 Aug; 17(1):604. PubMed ID: 28859615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience with eribulin in HR+/HER2- metastatic breast cancer, including a male.
    Mar Muñoz Sánchez MD; Carmen Soriano Rodríguez MD; Molina Garrido MJ; López-González A; García-Palomo A; López-González L; Plata Fernández MY; Caro NL; Rovira PS
    Future Oncol; 2018 Mar; 14(7s):5-12. PubMed ID: 29611755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience with eribulin in patients with metastatic breast cancer and associated hepatic impairment: case studies.
    Acosta-Eyzaguirre D; Calvo Plaza I; Perelló Martorell A; Hernández Agudo E; García-Estévez L
    Future Oncol; 2018 Mar; 14(7s):29-36. PubMed ID: 29611757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical benefit of treatment with eribulin mesylate for metastatic triple-negative breast cancer: Long-term outcomes of patients treated in the US community oncology setting.
    Mougalian SS; Copher R; Kish JK; McAllister L; Wang Z; Broscious M; Garofalo D; Radtchenko J; Feinberg BA
    Cancer Med; 2018 Sep; 7(9):4371-4378. PubMed ID: 30066497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with eribulin in the treatment of elderly women with metastatic breast cancer: case studies.
    Garrido ML; Morago AJ; Rovira PS; Olarte PE; Sánchez CP; Sánchez LM
    Future Oncol; 2018 Mar; 14(7s):21-27. PubMed ID: 29611758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness analysis of monotherapy with cytotoxic agents in triple-negative metastatic breast cancer in a community setting.
    Dranitsaris G; Gluck S; Faria C; Cox D; Rugo H
    Clin Ther; 2015 Jan; 37(1):134-44. PubMed ID: 25433768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eribulin as a Feasible and Safe Monotherapy in a Dialytic Pretreated Woman with Metastatic Breast Cancer: A Case Report.
    Nettuno R; Menditto C
    Oncology; 2018; 94 Suppl 1(Suppl 1):16-18. PubMed ID: 30036877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Eribulin in the treatment for metastatic breast cancer].
    Manzyuk LV; Kovalenko EI; Artamonova E
    Vopr Onkol; 2015; 61(2):195-8. PubMed ID: 26087597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience with eribulin in patients with breast cancer and cutaneous metastases: case studies.
    Espinosa Aunión R; Ramírez Ruda CA; Rodríguez López C; Curiel García T; García Saénz JÁ; López López R
    Future Oncol; 2018 Mar; 14(7s):37-44. PubMed ID: 29611759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review of Real-World effectiveness of eribulin for locally advanced or metastatic breast cancer.
    Chabot I; Zhao Q; Su Y
    Curr Med Res Opin; 2020 Dec; 36(12):2025-2036. PubMed ID: 33044090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer.
    Kashiwagi S; Asano Y; Goto W; Takada K; Takahashi K; Noda S; Takashima T; Onoda N; Tomita S; Ohsawa M; Hirakawa K; Ohira M
    PLoS One; 2017; 12(2):e0170634. PubMed ID: 28166544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial.
    Krasniqi E; Pizzuti L; Valerio MR; Capomolla E; Botti C; Sanguineti G; Marchetti P; Anselmi E; Tomao S; Giordano A; Ficorella C; Cannita K; Livi L; Meattini I; Mauri M; Greco F; Veltri EM; Michelotti A; Moscetti L; Giotta F; Lorusso V; Paris I; Tomao F; Santini D; Tonini G; Villa A; Gebbia V; Gamucci T; Ciliberto G; Sperduti I; Mazzotta M; Barba M; Vici P
    Int J Med Sci; 2021; 18(10):2245-2250. PubMed ID: 33859534
    [No Abstract]   [Full Text] [Related]  

  • 16. [A long-term response to eribulin].
    Patient M; Tsogou PTN; Roméo E; Bladé JS; de Jauréguiberry JP; Boudin L
    Bull Cancer; 2018; 105(7-8):636-638. PubMed ID: 29910045
    [No Abstract]   [Full Text] [Related]  

  • 17. Eribulin Mesylate for the Treatment of Metastatic Hormone-refractory and Triple-negative Breast Cancer: A Multi-institutional Real-world Report on Efficacy and Safety.
    Valerio MR; Arrivas Bajardi E; Arcara CC; Borsellino N; Lo Mauro M; Cipolla C; Santarpia M; Firenze A; Motta G; Vigneri P; Gebbia V
    Am J Clin Oncol; 2021 Mar; 44(3):105-108. PubMed ID: 33481372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eribulin mesylate in advanced breast cancer: retrospective review of a single institute experience.
    Martella F; Bacci C; Giordano C; Montagnani F; Gelain E; Rabatti L; Fioretto L
    Future Oncol; 2015; 11(15 Suppl):31-6. PubMed ID: 26235263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial.
    Aftimos P; Polastro L; Ameye L; Jungels C; Vakili J; Paesmans M; van den Eerenbeemt J; Buttice A; Gombos A; de Valeriola D; Gil T; Piccart-Gebhart M; Awada A
    Eur J Cancer; 2016 Jun; 60():117-24. PubMed ID: 27107326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effectiveness of eribulin chemotherapy for squamous cell carcinoma of the breast].
    Kashiwagi S; Okuno T; Ishihara S; Ishii M; Asano Y; Watanabe M; Morisaki T; Aomatsu N; Noda S; Kawajiri H; Nakano T; Kawakami N; Mitsukawa Y; Takashima T; Onoda N; Ishikawa T; Hirakawa K
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):2369-71. PubMed ID: 24394115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.